FDA Staff Decries Novartis' Cardiovascular Drug
FDA’s Cardiovascular and Renal Drugs Committee today will weigh whether to go along with agency staffers and recommend against approval of Novartis’ acute heart failure (AHF) drug candidate serelaxin—the treat…
Read guide →